Research News and Progress

Publications

Hearing problems in humans and mouse models with rare copy number variants associated with schizophrenia: a scoping review protocol [version 2; peer review: 2 approved, 1 approved with reservations]. Murtough S, Panconesi D, Lu C. et al. Wellcome Open Res. 2024;9:546. doi:10.12688/wellcomeopenres.23013.2

A systematic review of pharmacogenetic testing to guide antipsychotic treatment. Saadullah Khani N, Hudson G, Mills G, et al. Nat Ment Health. 2024;2(5):616-626. doi:10.1038/s44220-024-00240-2

Psychosis Endophenotypes: A Gene-Set-Specific Polygenic Risk Score Analysis. Wang B, Irizar H, Thygesen JH, et al. Schizophr Bull. 2023;49(6):1625-1636. doi:10.1093/schbul/sbad088

Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19/ CYP2D6 genes play a role? A UK population-based study. Richards-Belle A, Austin-Zimmerman I, Wang B, et al. J Psychopharmacol. 2023;37(4):396-407. doi:10.1177/02698811231152748

The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics. Austin-Zimmerman I, Wronska M, Wang B, et al. Genes (Basel). 2021;12(11):1758. doi:10.3390/genes12111758

Genetic copy number variants, cognition and psychosis: a meta-analysis and a family study. Thygesen JH, Presman A, Harju-Seppänen J, et al. Mol Psychiatry. 2021;26(9):5307-5319. doi:10.1038/s41380-020-0820-7

The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis. Calafato MS, Austin-Zimmerman I, Thygesen JH, et al. Pharmacogenomics J. 2020;20(5):629-637. doi:10.1038/s41397-019-0142-9

Effect of CYP1A2, CYP2D6, and CYP3A4 Variation on Antipsychotic Treatment Outcomes. Varney L, Murtough S, Cotic M, et al. Pharmaceuticals (Basel). 2025;18(6):892. Doi: 10.3390/ph18060892

Conference Attendence

World Congress of Psychiatric Genetics 2024 (Singapore)

Implementing ACKR1 variant testing in England for clozapine therapy. Murtough S, Mills D, Abidoph R, et al. Euro Neuro. 2024. doi:10.1016/j.euroneuro.2024.08.492

Adaptive-sampling nanopore sequencing in the G-PAT study: A multi-omics approach for the characterisation of rare pharmacogene variants in psychosis. Cotic M, Saadullah Khani N, Varney L, et al. Euro Neuro. 2024. doi:10.1016/j.euroneuro.2024.08.488

Cost-effectiveness analysis of pharmacogenetic testing to guide treatment in schizophrenia. Saadullah Khani N, Murtough S, Richards-Belle A, et al. Euro Neuro. 2024. doi:10.1016/j.euroneuro.2024.08.500

World Congress of Psychiatric Genetics 2023 (Canada)

Assessment of pharmacogenetic analysis technologies applied in the G-PAT study: Multi-modal characterisation of key pharmacogenes in the context of psychosis. Cotic M, Saadullah Khani N, Varney L, et al. Euro Neuro. 2023. doi:10.1016/j.euroneuro.2023.08.273

Polygenic scores and the relationship between cognition and psychosis. Varney L, Wang B, Cotic M, et al. Euro Neuro. 2023. doi:10.1016/j.euroneuro.2023.08.378

Pharmacogenetic testing to guide antipyschotic treatment: A systematic review and meta-analysis. Saadullah Khani N, Hudson G, Mills G, et al. Euro Neuro. 2023. doi:10.1016/j.euroneuro.2023.08.373

Other ongoing studies

The research team are also working on another study, Biomarkers for Psychosis and their Genetic Importance, which can be found here.

Contact

For all enquiries, please contact the UCL study team at gems@ucl.ac.uk or nlft.gems@nhs.net

Chief Investigator: Elvira Bramon, e.bramon@ucl.ac.uk

Link